All In Biotech

Drug Trial Radar · NCT05348577

Study of Capivasertib + Docetaxel vs Placebo + Docetaxel as Treatment for Metastatic Castration Resistant Prostate Cancer (mCRPC)

A Phase III Double-Blind, Randomised, Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Docetaxel Versus Placebo + Docetaxel as Treatment for Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)

Last checked: Nov 20, 2026Latest source record: Jan 27, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 1,035 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

1,035

Actual

Start

Mar 25, 2022

Primary completion

Mar 4, 2026

Study completion Mar 4, 2026

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
Apr 27, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 18 years, up to 130 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will assess the efficacy and safety of capivasertib plus docetaxel versus placebo plus docetaxel in participants with metastatic castration resistant prostate cancer (mCRPC), all participants will receive the docetaxel with steroid therapy and receive androgen deprivation therapy. The intention of the study is to demonstrate that the combination of capivasertib plus docetaxel is superior to placebo plus docetaxel with respect to the overall survival and/or the radiographic progression free survival of study participants.

Conditions

  • Prostate Cancer

Interventions

  • capivasertibDrug

    320 mg (2 tablets) BD given on an intermittent weekly dosing schedule. Patients will be dosed on Days 2 to 5, 9 to 12, and 16 to 19 in each week of a 21-day treatment cycle. Number of Cycles: until disease progression or unacceptable toxicity develops, death, or if the patient requests to stop the study treatment.

  • docetaxelDrug

    Patients will receive docetaxel in intravenous infusion, 75 mg/m2 BSA, on Day 1 of the 21-day cycles for up to 6 to 10 cycles, according to standard of care practices.

  • placeboOther

    matched to capivasertib appearance (2 tablets) BD given orally on an intermittent weekly dosing schedule. Patients will be dosed on Days 2 to 5, 9 to 12, and 16 to 19 in each week of a 21-day treatment cycle. Number of Cycles: until disease progression or unacceptable toxicity develops, death, or if the patient requests to stop the study treatment.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall Survival (OS) in the overall populationTime frame: up to approximately 46 months
  2. Radiographic Progression-free Survival (rPFS) in the overall populationTime frame: up to approximately 37 months

Locations

217 sites in 22 countries. Site status is shown where the registry gives one.

  • Research Site

    Yuma, Arizona

  • Research Site

    Beverly Hills, California

  • Research Site

    Cerritos, California

  • Research Site

    Fresno, California

  • Research Site

    Los Angeles, California

  • Research Site

    Sacramento, California

  • Research Site

    San Francisco, California

  • Research Site

    Santa Barbara, California

  • Research Site

    Santa Monica, California

  • Research Site

    Santa Rosa, California

  • Research Site

    Aurora, Colorado

  • Research Site

    Lakewood, Colorado

  • Research Site

    Littleton, Colorado

  • Research Site

    Baltimore, Maryland

  • Research Site

    Baltimore, Maryland

  • Research Site

    Minneapolis, Minnesota

  • Research Site

    Minneapolis, Minnesota

  • Research Site

    Hackensack, New Jersey

  • Research Site

    Albany, New York

  • Research Site

    The Bronx, New York

  • Research Site

    White Plains, New York

  • Research Site

    Toledo, Ohio

  • Research Site

    Portland, Oregon

  • Research Site

    Bala-Cynwyd, Pennsylvania

  • Research Site

    Philadelphia, Pennsylvania

  • Research Site

    Philadelphia, Pennsylvania

  • Research Site

    Greenville, South Carolina

  • Research Site

    Watertown, South Dakota

  • Research Site

    Chattanooga, Tennessee

  • Research Site

    Nashville, Tennessee

  • Research Site

    Austin, Texas

  • Research Site

    Dallas, Texas

  • Research Site

    Houston, Texas

  • Research Site

    Kingwood, Texas

  • Research Site

    San Antonio, Texas

  • Research Site

    Chesapeake, Virginia

  • Research Site

    Seattle, Washington

  • Research Site

    Birtinya, Australia

  • Research Site

    Greenslopes, Australia

  • Research Site

    Kogarah, Australia

Showing 40 of 217 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.